Xvivo Perfusion ABXVIPF -1.32%87 EV-to-EBITDA is 80.86 as of Jun. 30, 2026, which is 70% below its 10-year median of 269.31. GuruFocus rates XVIPF with a GF Score™ of 87/100 and a GF Value™ of $47.23 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 511 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 93.93% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Xvivo Perfusion AB's enterprise value is $812.07 Mil.
Xvivo Perfusion AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $10.04 Mil. Therefore, Xvivo Perfusion AB's EV-to-EBITDA for today is 80.86.
The historical rank and industry rank for Xvivo Perfusion AB's EV-to-EBITDA or its related term are showing as below:
XVIPF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -928.43 Med: 269.31 Max: 2461.25
Current: 84.91
During the past 13 years, the highest EV-to-EBITDA of Xvivo Perfusion AB was 2461.25. The lowest was -928.43. And the median was 269.31.
XVIPF's EV-to-EBITDA is ranked worse than 93.93% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 13.9
vs XVIPF: 84.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Xvivo Perfusion AB (OTCPK:XVIPF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xvivo Perfusion AB's PE Ratio (TTM) for today is calculated as:
Xvivo Perfusion AB's share price for today is $29.0011.
Xvivo Perfusion AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.252.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Xvivo Perfusion AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's EV-to-EBITDA falls into.
Xvivo Perfusion AB's current Enterprise Value is $812.07 Mil.
Xvivo Perfusion AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a EV-to-EBITDA of 80.86 as of Jun. 30, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Xvivo Perfusion AB. This is 70% below median its historical median of 269.31. According to the industry distribution chart, Xvivo Perfusion AB ranks #480 out of 511 companies in the Medical Devices & Instruments industry, placing it in the top 93.9%.
Is Xvivo Perfusion AB's EV-to-EBITDA too high?
Xvivo Perfusion AB's current EV-to-EBITDA of 80.86 is 70% below median its 10-year median of 269.31. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.90. Xvivo Perfusion AB's value of 80.86 is 481.7% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #480 out of 511 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #480 out of 511 companies for EV-to-EBITDA. This places Xvivo Perfusion AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.90. Xvivo Perfusion AB's value of 80.86 is 481.7% above this benchmark. While the company's 10-year median is 269.31 vs. the industry median of 13.90, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.90, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current EV-to-EBITDA of 80.86 is 481.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Xvivo Perfusion AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current EV-to-EBITDA is 80.86, which is 70% below median its own 10-year median of 269.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.23, compared to a current price of $29.00 — trading 38.6% below its estimated fair value. The current EV-to-EBITDA is 80.86, which is 70% below median its 10-year median of 269.31 and 481.7% above the Medical Devices & Instruments industry median of 13.90. Xvivo Perfusion AB's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current EV-to-EBITDA is 80.86 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 38.6% below its estimated GF Value™ of $47.23.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
EV-to-EBITDA: 80.86 (70% below median its 10-year median of 269.31)
GF Value™: $47.23 vs. price of $29.00 (38.6% below fair value)
Industry Position: 481.7% above the Medical Devices & Instruments median (#480 of 511)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
87GF Score
Get the complete analysis for XVIPF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
